{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-25-076501","form_type":"8-K","ticker":"BTAI","cik":"0001720893","company_name":"BioXcel Therapeutics, Inc.","filed_at":"2025-08-12T23:59:59+00:00","discovered_at":"2026-05-14T18:02:44.772948+00:00","generated_at":"2026-05-17T14:41:39.113362+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"BioXcel Q2 net loss $19.2M, cash $18.6M; SERENITY Phase 3 topline due August","bullets":["Q2 2025 IGALMI revenue $120K (down ~89% YoY from $1.1M); net loss $19.2M vs $8.3M in Q2 2024.","Operating loss improved to $15.9M from $17.3M YoY; R&D spending up to $10.3M from $8.0M.","Cash and equivalents $18.6M at June 30; post-quarter raised $11.5M from ATM and $3.6M from warrant exercises.","SERENITY At-Home Phase 3 trial for bipolar/schizophrenia complete; topline results expected August 2025.","FDA meeting in August to support potential sNDA for label expansion of IGALMI to at-home setting."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-25-076501","json":"https://secwatch.observer/filing/0001104659-25-076501.json","markdown":"https://secwatch.observer/filing/0001104659-25-076501.md","text":"https://secwatch.observer/filing/0001104659-25-076501.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1720893/000110465925076501/0001104659-25-076501-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1720893/000110465925076501/tm2523230d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T14:41:39.113362+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}